secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001493152-22-031383
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus Q3 2022: cash $28.5M, loss $0.42/share; Decoy20 Phase 1 to start Q4 2022
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities of $28.5M as of Sep 30, 2022, down from $39.1M at Dec 31, 2021.
- R&D expenses of $1.6M in Q3 2022, up $900K vs Q3 2021, driven by Phase 1 trial preparation and manufacturing costs.
- G&A expenses of $2.0M in Q3 2022, down $700K vs Q3 2021, due to lower merger-related costs.
- Loss per share of $0.42 in Q3 2022 vs $0.81 in Q3 2021; net loss of $2.3M for the quarter.
- Phase 1 trial of Decoy20 for solid tumors remains on track to initiate in Q4 2022 after FDA IND clearance in May.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315222031383/0001493152-22-031383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315222031383/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-031383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer